X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with ALEMBIC PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ALEMBIC PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ALEMBIC PHARMA DISHMAN PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 25.1 29.2 86.1% View Chart
P/BV x 3.3 6.7 50.3% View Chart
Dividend Yield % 0.7 0.7 93.8%  

Financials

 DISHMAN PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ALEMBIC PHARMA
Mar-16
DISHMAN PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs374792 47.3%   
Low Rs129443 29.1%   
Sales per share (Unadj.) Rs197.8167.0 118.4%  
Earnings per share (Unadj.) Rs21.238.2 55.6%  
Cash flow per share (Unadj.) Rs34.742.0 82.7%  
Dividends per share (Unadj.) Rs2.004.00 50.0%  
Dividend yield (eoy) %0.80.6 122.7%  
Book value per share (Unadj.) Rs179.984.9 211.9%  
Shares outstanding (eoy) m80.69188.52 42.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.33.7 34.4%   
Avg P/E ratio x11.916.2 73.4%  
P/CF ratio (eoy) x7.214.7 49.3%  
Price / Book Value ratio x1.47.3 19.2%  
Dividend payout %9.410.5 90.0%   
Avg Mkt Cap Rs m20,306116,383 17.4%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,3554,214 127.1%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,96131,487 50.7%  
Other income Rs m26555 481.7%   
Total revenues Rs m16,22631,542 51.4%   
Gross profit Rs m4,10310,060 40.8%  
Depreciation Rs m1,091722 151.0%   
Interest Rs m94437 2,566.3%   
Profit before tax Rs m2,3349,356 24.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m1-2 -73.3%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6242,160 28.9%   
Profit after tax Rs m1,7117,194 23.8%  
Gross profit margin %25.731.9 80.5%  
Effective tax rate %26.723.1 115.7%   
Net profit margin %10.722.8 46.9%  
BALANCE SHEET DATA
Current assets Rs m11,01815,066 73.1%   
Current liabilities Rs m9,5177,674 124.0%   
Net working cap to sales %9.423.5 40.1%  
Current ratio x1.22.0 59.0%  
Inventory Days Days11067 165.0%  
Debtors Days Days3541 85.7%  
Net fixed assets Rs m16,3048,237 197.9%   
Share capital Rs m161377 42.8%   
"Free" reserves Rs m12,90715,416 83.7%   
Net worth Rs m14,51616,005 90.7%   
Long term debt Rs m4,1890-   
Total assets Rs m29,80524,594 121.2%  
Interest coverage x3.5255.2 1.4%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.3 41.8%   
Return on assets %8.929.4 30.3%  
Return on equity %11.844.9 26.2%  
Return on capital %17.558.7 29.9%  
Exports to sales %24.855.7 44.5%   
Imports to sales %3.710.4 35.8%   
Exports (fob) Rs m3,95617,551 22.5%   
Imports (cif) Rs m5963,283 18.2%   
Fx inflow Rs m4,95217,811 27.8%   
Fx outflow Rs m6975,318 13.1%   
Net fx Rs m4,25512,493 34.1%   
CASH FLOW
From Operations Rs m2,7869,304 29.9%  
From Investments Rs m-1,529-3,105 49.2%  
From Financial Activity Rs m-941-1,959 48.0%  
Net Cashflow Rs m3164,240 7.5%  

Share Holding

Indian Promoters % 61.4 74.1 82.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 2.9 127.6%  
FIIs % 12.7 9.1 139.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 13.9 159.0%  
Shareholders   46,261 49,328 93.8%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   DIVIS LABORATORIES  GLENMARK PHARMA  DR. REDDYS LAB  ELDER PHARMA  UNICHEM LAB  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Lower; Energy Stocks Witness Losses(11:30 am)

Share markets in India are presently trading marginally lower. Sectoral indices are trading on a mixed note with stocks in the energy sector and auto sector witnessing maximum selling pressure.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS